Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) insider Samuel C. Blackman sold 50,000 shares of the business’s stock in a transaction on Wednesday, June 15th. The shares were sold at an average price of $16.26, for a total transaction of $813,000.00. Following the sale, the insider now owns 1,316,718 shares of the company’s stock, valued at approximately $21,409,834.68. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of DAWN stock opened at $15.79 on Friday. The firm has a fifty day simple moving average of $9.09 and a two-hundred day simple moving average of $12.31. Day One Biopharmaceuticals, Inc. has a 12 month low of $5.44 and a 12 month high of $28.70.
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.09). Analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.05 EPS for the current year.
Separately, Wedbush boosted their price target on shares of Day One Biopharmaceuticals from $32.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, June 13th.
About Day One Biopharmaceuticals (Get Rating)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- Ride Out The Recession With These Dividend Kings
- MarketBeat: Week in Review 6/13 – 6/17
- eBay’s Long Term Fundamentals Are Intact If You Can Stomach Short Term Volatility
- Honda’s Stock Continues To Fly Under The Radar
- Vuzix Stock Stays Optimistic
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.